Achilles Therapeutics AI-Powered Precision Cell Therapy Targeting All Tumor Cells March 2023 Non-Confidential © Achilles Therapeutics plc 2023 Forward-Looking Statements / Disclaimers This presentation contains “forward-looking statements,” including statements regarding the proposed development plans and timelines for the Company’s product candidates and the success, cost and timing of its research activities and clinical trials. Forward-looking statements can generally be identified by the use of words su ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissi ...

Achilles Therapeutics AI-Powered Precision TIL Therapy April 2022 © Achilles Therapeutics plc 2022 Forward-Looking Statements This presentation contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 * Not for trading, but only in connection with the registration of the American Depositary Shares. Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ S ...

Achilles Therapeutics plc (NASDAQ:ACHL) SITC & Corporate Update Call November 12, 2021 8:30 AM ET Company Participants Lee Stern - VP, IR & External Communications Iraj Ali - CEO Karl Peggs - CMO Sergio Quezada - CSO Samra Turajlic - Chief Investigator, THETIS Conference Call Participants Joe Catanzaro - Piper Sandler Tazeen Ahmad - Bank of America Ingrid Gafanhao - Kempen Lee Stern We are glad you joined us for our review of today's SITC presentations and a brief corporate update. Prior to this call we iss ...